Recent Updates
Recently added Catalysts
FATE Negative Sentiment Score: 25/100

FATE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

Key Takeaway: Kahn Swick & Foti, LLC has launched an investigation into Fate Therapeutics, Inc. to determine if its executives breached fiduciary duties to shareholders. This follows a significant termination of their collaboration with Janssen Biotech, which included a $50 million payment and potential future earnings exceeding $3 billion. The investigation is compounded by a pending securities class action lawsuit concerning allegations of undisclosed material information. Additionally, the company has laid off employees and ceased multiple cancer programs, raising concerns about its operational stability.

Market Sentiment Analysis

CONCERNS & RISKS

  • Former Attorney General is investigating Fate Therapeutics' executives.
  • Company recently terminated a major collaboration with Janssen Biotech.
  • Securities class action lawsuit alleges failure to disclose material information.
  • Fate has reduced its workforce and discontinued several cancer programs.

Full Press Release Details

NEW ORLEANS, June 16, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics, Inc. (NasdaqGM: FATE).
On April 2, 2020, the Company announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment and was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. Then, on January 5, 2023, the Company disclosed that it had terminated the Janssen Agreement and that all licenses and other rights granted pursuant to the Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains pending.
KSF’s investigation is focusing on whether Fate’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Fate Therapeutics shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-fate/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is Kahn Swick & Foti, LLC investigating?

KSF is investigating Fate Therapeutics, Inc. for potential fiduciary breaches by its officers.

Why did Fate Therapeutics terminate its agreement with Janssen?

Fate announced the termination of its agreement with Janssen on January 5, 2023.

What lawsuit is pending against Fate Therapeutics?

Fate Therpeutics faces a securities class action lawsuit for failing to disclose key information.

What should I do if I have information on the investigation?

Contact KSF at 1-833-938-0905 or email Lewis Kahn to provide information.

What kind of clients does KSF serve?

KSF serves public investors, hedge funds, and retail investors seeking recoveries from fraud.

Last updated: Jun 17, 2023